Reconstruction of apo A2A receptor activation pathways reveal ligand-competent intermediates and state-dependent cholesterol hotspots.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
02 10 2019
Historique:
received: 29 05 2019
accepted: 27 08 2019
entrez: 4 10 2019
pubmed: 4 10 2019
medline: 3 11 2020
Statut: epublish

Résumé

G-protein coupled receptors (GPCRs) play a pivotal role in transmitting signals at the cellular level. Structural insights can be exploited to support GPCR structure-based drug discovery endeavours. Despite advances in GPCR crystallography, active state structures are scarce. Molecular dynamics (MD) simulations have been used to explore the conformational landscape of GPCRs. Efforts have been made to retrieve active state conformations starting from inactive structures, however to date this has not been possible without using an energy bias. Here, we reconstruct the activation pathways of the apo adenosine receptor (A2A), starting from an inactive conformation, by applying adaptive sampling MD combined with a goal-oriented scoring function. The reconstructed pathways reconcile well with experiments and help deepen our understanding of A2A regulatory mechanisms. Exploration of the apo conformational landscape of A2A reveals the existence of ligand-competent states, active intermediates and state-dependent cholesterol hotspots of relevance for drug discovery. To the best of our knowledge this is the first time an activation process has been elucidated for a GPCR starting from an inactive structure only, using a non-biased MD approach, opening avenues for the study of ligand binding to elusive yet pharmacologically relevant GPCR states.

Identifiants

pubmed: 31578448
doi: 10.1038/s41598-019-50752-6
pii: 10.1038/s41598-019-50752-6
pmc: PMC6775061
doi:

Substances chimiques

Adenosine A2 Receptor Agonists 0
Ligands 0
Receptor, Adenosine A2A 0
Receptors, G-Protein-Coupled 0
Cholesterol 97C5T2UQ7J

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

14199

Références

Nature. 2018 Jul;559(7712):45-53
pubmed: 29973731
Proteins. 2009 Aug 1;76(2):403-17
pubmed: 19173312
Nat Chem. 2014 Jan;6(1):15-21
pubmed: 24345941
Drug Discov Today. 2006 Jun;11(11-12):481-93
pubmed: 16713899
Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):2066-2071
pubmed: 28167788
Adv Exp Med Biol. 2014;796:75-94
pubmed: 24158802
J Chem Inf Model. 2014 Feb 24;54(2):372-6
pubmed: 24456045
Pharmacol Ther. 2003 Jul;99(1):25-44
pubmed: 12804697
Nat Struct Mol Biol. 2018 Jan;25(1):4-12
pubmed: 29323277
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):10982-7
pubmed: 23781107
Trends Pharmacol Sci. 2007 Aug;28(8):397-406
pubmed: 17629961
Structure. 2011 Sep 7;19(9):1283-93
pubmed: 21885291
Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):12733-12738
pubmed: 30463958
J Chem Inf Model. 2016 Apr 25;56(4):687-705
pubmed: 27019343
Science. 2012 Jul 13;337(6091):232-6
pubmed: 22798613
Structure. 2019 Feb 5;27(2):392-403.e3
pubmed: 30581046
BMC Cell Biol. 2012 Mar 19;13:6
pubmed: 22429589
Drug Discov Today. 2016 Apr;21(4):625-31
pubmed: 26821135
J Am Chem Soc. 2012 Oct 10;134(40):16512-5
pubmed: 23005256
Nat Chem Biol. 2012 Jul 18;8(8):674-7
pubmed: 22810762
J Med Chem. 2016 Jul 14;59(13):6470-9
pubmed: 27312113
Purinergic Signal. 2012 Dec;8(4):677-92
pubmed: 22476939
Nature. 2017 May 18;545(7654):317-322
pubmed: 28489817
Angew Chem Int Ed Engl. 2019 Jul 8;58(28):9399-9403
pubmed: 31095849
Mol Inform. 2016 Jul;35(6-7):227-37
pubmed: 27492237
Elife. 2018 May 04;7:
pubmed: 29726815
Nat Rev Drug Discov. 2010 May;9(5):373-86
pubmed: 20431569
J Am Chem Soc. 2011 Nov 16;133(45):18413-9
pubmed: 21988563
Biochemistry. 1993 Mar 9;32(9):2438-54
pubmed: 8443184
Sci Rep. 2017 Sep 12;7(1):11255
pubmed: 28900175
Science. 2008 Nov 21;322(5905):1211-7
pubmed: 18832607
Nature. 2016 May 04;533(7602):265-8
pubmed: 27144352
Nature. 2016 Aug 4;536(7614):104-7
pubmed: 27462812
Mol Pharmacol. 2002 Feb;61(2):455-62
pubmed: 11809871
Biophys J. 2014 Mar 18;106(6):1290-300
pubmed: 24655504
Trends Pharmacol Sci. 1995 Mar;16(3):89-97
pubmed: 7540781
J Am Chem Soc. 2013 Jun 12;135(23):8749-59
pubmed: 23678995
Nat Commun. 2017 Feb 21;8:14505
pubmed: 28220900
Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18684-9
pubmed: 22031696
J Chem Theory Comput. 2015 Dec 8;11(12):5747-57
pubmed: 26588361
J Chem Theory Comput. 2009 Jun 9;5(6):1632-9
pubmed: 26609855
Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):19011-6
pubmed: 19887634
J Chem Theory Comput. 2016 Apr 12;12(4):1845-52
pubmed: 26949976
Protein Sci. 2015 Jun;24(6):1004-12
pubmed: 25761901
Protein Sci. 2014 Jan;23(1):1-22
pubmed: 24155031
ACS Chem Neurosci. 2011 Oct 19;2(10):555-67
pubmed: 22860156
J Chem Theory Comput. 2014 May 13;10(5):2064-9
pubmed: 26580533
Science. 2010 Jan 1;327(5961):46-50
pubmed: 20044567
Nature. 2011 May 18;474(7352):521-5
pubmed: 21593763
J Chem Inf Model. 2013 May 24;53(5):1168-78
pubmed: 23514445
Biochim Biophys Acta Biomembr. 2017 Feb;1859(2):268-281
pubmed: 27919726
Nat Rev Drug Discov. 2017 Dec;16(12):829-842
pubmed: 29075003
Annu Rev Pharmacol Toxicol. 2013;53:531-56
pubmed: 23140243
J Comput Chem. 2013 Sep 30;34(25):2135-45
pubmed: 23832629

Auteurs

Silvia Lovera (S)

CADD, UCB BioPharma, 1420, Braine l'Alleud, Belgium. silvia.lovera@ucb.com.

Alberto Cuzzolin (A)

Acellera, Barcelona Biomedical Research Park (PRBB), C/Doctor Aiguader 88, 08003, Barcelona, Spain.

Sebastian Kelm (S)

CADD, UCB Pharma, Slough, UK.

Gianni De Fabritiis (G)

Acellera, Barcelona Biomedical Research Park (PRBB), C/Doctor Aiguader 88, 08003, Barcelona, Spain.
Computational Science Laboratory (GRIB-IMIM), Universitat Pompeu Fabra, Barcelona Biomedical Research Park (PRBB), C/Doctor Aiguader 88, 08003, Barcelona, Spain.
Institució Catalana de Recerca i Estudis Avançats (ICREA), Passeig Lluis Companys 23, 08010, Barcelona, Spain.

Zara A Sands (ZA)

CADD, UCB BioPharma, 1420, Braine l'Alleud, Belgium. zara.sands@ucb.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH